Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD1 | O95696 | 1/20 | 0.31 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27893468 | 0.84 | SMN1; SMN2 (0.41) | KDM4ETSHRHRH3MEN1KMT2A | |
| SCHEMBL30335980 | 0.83 | CHRM5 (0.33) | CHRM5CHRM3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17152994 | 0.83 | PLA2G10 (0.35) | HRH3SIGMAR1 | |
| SCHEMBL5156687 | 0.81 | SLC6A9 (0.41) | DPP4HTR2C | |
| SCHEMBL1666880 | 0.81 | DPP4 (0.33) | CHRM5CHRM3KDM4EDPP4SIGMAR1 | |
| Hydrochloric Acid SCHEMBL28060538 | 0.79 | SLC6A9 (0.40) | DPP4HTR2C | |
| SCHEMBL5900537 | 0.79 | DPP4 (0.32) | CHRM5CHRM3DPP4 | |
| SCHEMBL30403488 | 0.78 | GRM2 (0.35) | KDM4EHTTSIGMAR1HTR2C | |
| SCHEMBL29170258 | 0.78 | GRM2 (0.35) | KDM4EHTTSIGMAR1HTR2C | |
| SCHEMBL29170253 | 0.78 | GRM2 (0.35) | KDM4EHTTSIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | HOFFMANN-LA ROCHE INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3826724-B1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2022-10-05 | — | — | EP | disclosed |
| EP-3826724-B1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2022-10-05 | — | — | EP | disclosed |
| CN-112584903-A | Novel piperazine compounds for the treatment of autoimmune diseases | 豪夫迈·罗氏有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020020800-A1 | NOVEL PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952363-B2 | Piperazine compounds for the treatment of autoimmune disease | SSB, HLA-DRB1, IL5 | CHRM5 1548/4885CHRM3 2135/4885CHRNB2 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.